Frontier AI firm Profluent has entered a multi-program strategic research collaboration with Eli Lilly and Co. (NYSE:LLY) to develop and commercialize custom site-specific recombinases to treat genetic diseases.
The partnership centers on advancing precise, large-scale DNA editing technologies that conventional gene editing methods have yet to achieve.
Deal Economics And Industry Implications
Financially, Profluent will receive an upfront payment along with committed research and development funding.
The company is also eligible for up to $2.25 billion in milestone payments tied to development and commercialization. There are also tiered royalties on future net sales.
The collaboration reflects increasing pharmaceutical industry interest in AI-enabled platforms.
Targeting Limitations Of Traditional Gene Editing
The collaboration seeks to address a core challenge in genetic medicine: many diseases stem from diverse mutations across patient populations, complicating the development of universal therapies.
While large-scale DNA editing—such as inserting entire genes at specific genomic sites—offers a potential solution, it remains a largely unsolved technical hurdle.
Traditional gene editing approaches rely on naturally occurring enzymes, which may not align with desired genomic targets. Profluent is instead leveraging artificial intelligence to design custom recombinases engineered to act on precise DNA locations.
AI Models Meet Clinical Development Expertise
Under the agreement, Profluent will deploy its AI-driven platform to design and optimize recombinases for multiple genomic targets.
Eli Lilly will receive exclusive rights to advance selected candidates through in vivo studies, preclinical work, clinical trials, and eventual commercialization.
Ali Madani, co-founder and CEO of Profluent, described kilobase-scale DNA editing as a "holy grail" in genetic medicine, emphasizing that AI-driven design could enable therapies previously considered unattainable.
Platform Potential Across Disease Categories
Hilary Eaton, Profluent's Chief Business Officer, noted that existing gene editing methods fail to address entire categories of diseases. She said the company's generative AI models—trained on extensive protein datasets—are designed to unlock broader applications across both rare and common conditions.
LLY Price Action: Eli Lilly shares were down 0.35% at $865.21 at the time of publication on Tuesday, according to Benzinga Pro data.
Photo: Jonathan Weiss / Shutterstock
Login to comment